THEMISMEDBSETHEMIS MEDICARE LTD.MediumNeutral
Announced Thu, 13 Aug · 12:53 IST

Themis Medicare Q1 PAT at Rs 28.74 cr on share sale gain, new CS appointed

Board & Shareholder Meetings View source PDFExplain this filing

THEMISMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.6%1-day move
₹107.25
prior close
₹111.15
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-3.7-3.3-1.6-6.9-2.6-0.2-1.2-2.2-4.0+12.4+15.9+12.0
Up moveDown movePending
AI summary

Themis Medicare Q1 FY27 standalone PAT came in at Rs 28.74 cr vs a loss of Rs 15.37 cr last year, boosted by a one-time Rs 99.67 cr gain from selling shares in associate Gujarat Themis Biosyn for Rs 100 cr. Underlying core business pre-tax loss widened to Rs 56.94 cr from Rs 13.92 cr. Revenue declined to Rs 86.96 cr from Rs 97.58 cr. Consolidated PAT was Rs 24.61 cr vs a loss of Rs 14.22 cr. Board accepted Nagraj Mogaveera's resignation as interim Company Secretary and appointed Suresh Savaliya (CS with 23 years experience at Reliance and Essel Group) as new Company Secretary effective 13 Aug 2026.

Likely market impact

PAT swing is from a one-time share sale gain, not core operations. Underlying losses widened. New CS brings strong listed-company compliance experience.